Clinical trials: Phase I
Healthy
A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants
The purpose of this study is to assess the rate and extent of absorption of macitentan following administration of a single oral dose of macitentan formulated as final market image (FMI) (test), compared to macitentan as the…
- Trial name
- NCT04963439
- Testing
- Macitentan
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Actelion
Healthy
A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.
This is a drug-drug interaction study to compare the pharmacokinetics of a 2 mg oral dose of midazolam in adult healthy women of non-childbearing potential when administered alone and when administered along with 8 daily 125 mg…
- Trial name
- NCT01756781
- Testing
- Midazolam, PD-0332991
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Intrahepatic Cholangiocarcinoma
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers
- Trial name
- NCT05930119
- Testing
- HMPL-453, Rabeprazole
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Asthma
A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma
This is a phase 1, safety study of CNTO 3157 in healthy subjects and subjects with asthma.
- Trial name
- NCT01195207
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Obesity, Overweight
A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
This study is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial. This study consists of two parts: the single-dose escalation study (SAD) in healthy subjects and the multiple-dose escalation…
- Trial name
- NCT07280936
- Testing
- SHR-2906 Injection
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Healthy
Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of HS-10360 in Healthy Subjects.
The primary objective of this study is to assess the safety and tolerability of single and multiple oral administered doses of HS-10360 in healthy subjects.
- Trial name
- NCT04986436
- Testing
- HS-10360
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Healthy Participants
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
This trial is conducted in China. This study will be conducted to evaluate pharmacokinetic/pharmacodynamic characteristics and safety of single administration of GZR101-80 Injection with separately injected, simultaneous doses of…
- Trial name
- NCT07918898
- Testing
- GZR101 80 Injection, GZR33 Injection, Insulin Aspart Injection
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine
The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of Repaglinide and possible metabolites after single dose administration.
- Conditions
- Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine, Healthy Subjects
- Trial name
- NCT02128321
- Testing
- Isavuconazole, Repaglinide, Caffeine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy Participants
A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234.
- Trial name
- NCT07911514
- Testing
- AZD9550 solution for injection, AZD6234 solution for injection, Formulation 1 solution for injection
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ
The current study will estimate any inhibitive or inductive effect of PF-06651600 on the pharmacokinetics of midazolam and efavirenz.
- Trial name
- NCT03762928
- Testing
- PF-06651600, midazolam, efavirenz
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Single and Multiple Dose Study to Evaluate the Safety and Effects of Inhaled ICF001 Dry Powder in Healthy Participants
The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetic characteristics of ICF001 following inhaled administration of single and multiple ascending doses in healthy participants.
- Trial name
- NCT07804628
- Testing
- ICF001
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- VIVID CLINICAL SERVICES PTY LTD
Renal Impairment
A Renal Impairment Study for PF-06651600
This is a Phase 1 non-randomized, open-label, parallel cohort study of PF-06651600 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with mild and moderate renal impairment…
- Trial name
- NCT04037865
- Testing
- PF-06651600
- Where
- 3 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Covid19, SARS CoV 2 Infection
Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)
This is a first-in-human, phase I/IIa, randomized, controlled, observer-blinded, dose-escalation, multicentre clinical trial to evaluate safety and immunogenicity of COVID-19 HIPRA vaccine in adult healthy volunteers.
- Trial name
- NCT05007509
- Testing
- COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40
- Where
- 2 sites in Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Hipra, S.A.
Drug Drug Interaction
Drug-Drug Interaction (DDI) Study in Healthy Volunteers
A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of BLD-0409 on the Single Dose Pharmacokinetics of a Cocktail of Probe Substrates for CYP450 Enzymes in Healthy Volunteers
- Trial name
- NCT04814498
- Testing
- Geneva Cocktail, BLD-0409
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Blade Therapeutics
Healthy, PK Drug-drug Interaction Study
Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension
This study has been designed to assess the safety, tolerability, and pharmacokinetics of a therapeutic dose of hydrocodone bitartrate with and without an oral dose of doxapram hydrochloride in healthy volunteers who are…
- Trial name
- NCT06585163
- Testing
- Hydrocodone Bitartrate, Hydrocodone Bitartrate + Doxapram Hydrochloride
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Quivive Pharma, Inc.
Hepatic Impairment, Healthy Volunteers
A Study of TAK-279 in Adults With or Without Liver Damage
The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with liver problems compared to participants without liver problems.
- Trial name
- NCT05976321
- Testing
- TAK-279
- Where
- 4 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Volunteers
A Study of FB1003 in Healthy and Osteoarthritis Pain Subjects
The purpose of Part 1 is to evaluate safety and tolerability of FB1003 when given subcutaneously to healthy participants. Blood tests will be done to examine blood exposure, concentration and half-life of FB1003 following…
- Trial name
- NCT06343714
- Testing
- FB1003
- Where
- 2 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- 4B Technologies Limited
Renal Impairment
A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are…
- Trial name
- NCT05844228
- Testing
- VIR-2218
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Atopic Dermatitis
A Single-center, Randomized, Double-blinded, Placebo-controlled, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of NCP112
To evaluate safety, tolerability and pharmacokinetics of NCP 112 after single and multiple applications on the skin of healthy male volunteers.
- Trial name
- NCT05638165
- Testing
- NCP112
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- NovaCell Technology Inc.
Skin Roughness, Wrinkle
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
- Conditions
- Skin Roughness, Wrinkle, Fine Lines, Skin Thickness
- Trial name
- NCT04540900
- Testing
- KB301
- Where
- 4 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Krystal Biotech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.